ASCO26: With daraxonrasib in the spotlight, Immuneering makes case for its drug in 1L pancreatic cancer

At ASCO 2026, Immuneering is presenting new survival data for its drug atebimetinib in combination with modified gemcitabine/nab‑paclitaxel (mGnP) in first‑line metastatic pancreatic cancer, while daraxonrasib from Revolution Medicines has dominated the second‑line conversation with phase 3 data showing it nearly doubles overall survival and progression‑free survival over chemotherapy in previously treated patients.

Immuneering reported a median overall survival of 17.3 months in 55 first‑line patients receiving atebimetinib plus mGnP, positioning its MEK‑targeted combination as a potential new standard in the first‑line setting, especially as daraxonrasib is still focused on second‑line and is being studied in first‑line trials such as RASolute 303.

Daraxonrasib data, presented in the plenary session of ASCO 2026, show median overall survival of 13.2 months versus 6.7 months with chemotherapy (HR 0.40) and median PFS of about 7.2–7.3 months versus 3.5–3.6 months, with a more favorable safety profile than chemotherapy, which has led many oncologists to call for an immediate shift in second‑line standard of care for metastatic pancreatic cancer.